{"id":"W3088078660","doi":"10.1200/jco.20.00948","title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"National Cancer Institute; University of California, San Diego; University of Texas MD Anderson Cancer Center; National Institutes of Health; Apellis Pharmaceuticals; BeiGene; National Comprehensive Cancer Network; University of Nebraska Medical Center; Universiteit van Amsterdam; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Gilead Sciences; Teva Pharmaceutical Industries; MorphoSys; Celgene; Pharmacyclics; Genentech; California Institute for Regenerative Medicine; AstraZeneca; Loxo Oncology; TG Therapeutics; Amgen; Breast Cancer Research Foundation","keywords":"Medicine; Venetoclax; Internal medicine; Bendamustine; Rituximab; Chronic lymphocytic leukemia; Regimen; Hazard ratio; Oncology; Progression-free survival; Gastroenterology; Alemtuzumab; Minimal residual disease; Leukemia; Chemotherapy; Lymphoma; Confidence interval; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004577626,0.0004829807,0.001321966,0.0003213171,0.000221828,0.0005760616,0.00051954,0.0006181948,0.0007091512],"category_scores_gemma":[0.002195984,0.0002047904,0.001167918,0.0003180999,0.0004591282,0.0003288168,0.0002722026,0.000965261,0.0001517076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006839253,"about_ca_system_score_gemma":0.0005112542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008988248,"about_ca_topic_score_gemma":0.001889635,"domain_scores_codex":[0.9984156,0.001131788,0.00006396906,0.0001241238,0.0001515204,0.0001131017],"domain_scores_gemma":[0.9978476,0.0007717267,0.0006449831,0.0002571852,0.00009417833,0.0003843174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6871876,0.01073177,0.09995686,0.0006888366,0.004143749,0.0002182266,0.0002913422,0.002573164,0.01467487,0.0001758728,0.001376982,0.1779808],"study_design_scores_gemma":[0.1708218,0.4711107,0.3434008,0.0001564381,0.003434547,0.0005577814,0.000108299,0.002379932,0.003181791,0.0002750204,0.004512563,0.00006043333],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948304,0.004101959,0.0001228444,0.00008325763,0.00002362631,0.0001377504,0.0001925899,0.000008560557,0.0004990918],"genre_scores_gemma":[0.9970332,0.001208156,0.0003012292,0.0001982003,0.00007273443,0.000150871,0.0005964203,0.000005000292,0.0004342246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004577626,"threshold_uncertainty_score":0.02420908,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2785272315645372,"score_gpt":0.5228803570445849,"score_spread":0.2443531254800477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}